Form 4: AbbVie Director Robert J. Alpern Acquires Additional Stock Equivalent Units

AbbVie Inc. Director Robert J. Alpern has acquired 40 additional stock equivalent units as part of his director compensation, increasing his total beneficial ownership to 10,038 units.

Summary

• Robert J. Alpern, a Director at AbbVie Inc. (ABBV), acquired 40 stock equivalent units on June 30, 2025.
• These units were credited as director fees to stock equivalent unit accounts under grantor trusts established at both Abbott Laboratories and AbbVie.
• Each unit was valued at $185.62, reflecting the price of AbbVie common stock.
• The stock equivalent units are designed to earn the same return as if the fees were invested directly in AbbVie stock.
• These units will be paid out in cash, generally upon the director reaching age 65 or retiring from the respective boards.
• Following this transaction, Robert J. Alpern beneficially owns a total of 10,038 stock equivalent units, which includes units acquired through a dividend reinvestment feature.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation disclosure, indicating ongoing director involvement and alignment with shareholder interests, without any negative implications.

Positives

• The acquisition of stock equivalent units aligns the director's interests with those of shareholders, as the units' value is tied to AbbVie's stock performance.
• The transaction represents a routine compensation mechanism for directors, indicating stable corporate governance practices.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction; it solely reports an insider transaction.

Industry Context

The practice of compensating directors with stock equivalent units is a common mechanism across various industries, including the pharmaceutical and biotechnology sectors, to align the interests of board members with long-term shareholder value. This type of compensation structure is prevalent among large, established companies like AbbVie.

Comparison to Industry Standards

• Director compensation through stock equivalent units, where units accrue value based on company stock performance and are paid out in cash upon retirement or a specific age, is a standard practice in large-cap pharmaceutical companies and aligns with common corporate governance benchmarks.
• While specific compensation amounts vary by company size, performance, and board responsibilities, the mechanism itself is consistent with industry norms for attracting and retaining experienced board members.

Related Party Transactions

• The acquisition of stock equivalent units by Director Robert J. Alpern represents compensation for his services, which is a standard related party transaction between the company and its board member.

Stakeholder Impact

• Shareholders: The acquisition of stock equivalent units by a director generally signals continued alignment of management interests with shareholder value, as the director's compensation is tied to the company's stock performance.

Key Dates

Keywords

AbbVie, ABBV, Form 4, Insider Transaction, Director Compensation, Stock Equivalent Units, Executive Compensation, Corporate Governance